IMPlementation of Continuous Glucose Monitoring in Children With Type 2 Diabetes
| Registry | NCT04721158, acronym IMPaCT2 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; na, single group, masking: none, supportive care |
| Enrollment | 41 (Actual) |
| Sponsor | Johns Hopkins University (Other) |
| Conditions | Type 2 Diabetes, Hyperglycemia Due to Type 2 Diabetes Mellitus |
| Interventions | Continuous glucose monitor (Device) |
| Dates | start 2021-01-17, primary completion 2022-07-28, completion 2022-07-28, first posted 2021-01-22, last updated 2023-09-15 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Type 2 Diabetes All trials for Hyperglycemia Due to Type 2 Diabetes Mellitus All trials of Continuous glucose monitor
The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system for a 10 day wear period in pediatric Type 2 diabetes patients improves short term time in range glucose control and 3-6 month glycemic control.
The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system for 10 days has an impact on short and long term glycemic control and behavior in youth onset Type 2 diabetes.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| CGM Arm | Other | Device: Continuous glucose monitor | Children with type 2 diabetes will wear a continuous glucose monitor for 10 days. |
Sex: All, ages: 5 Years to 21 Years
Inclusion Criteria: * Type 2 diabetes, diabetes duration >3 months Exclusion Criteria: * Prior use of CGM
| Milestone | CGM Sample Given |
|---|---|
| Started | 41 |
| Completed | 36 |
| Not completed | 5 |
Time frame: 6 months
| Arm | Deaths | Serious adverse events | Other adverse events |
|---|---|---|---|
| CGM Arm | 0/41 (0.0%) | 2/41 (4.9%) | 0/41 (0.0%) |
| Term | Organ system | CGM Arm |
|---|---|---|
| DKA admission | Endocrine disorders | 2/41 |
Limitations and caveats: The limitations of this study include the small study size with a limited number of participants completing both 10-day trial period and 3/6-month follow up visits. There were a large number of patients who had device connectivity and adhesive issues. Many participants were lost to follow up.
| Facility | City | Country | Status |
|---|---|---|---|
| Johns Hopkins Pediatric Diabetes Center | Baltimore, Maryland | United States |